OGN Stock Recent News
OGN LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25; +20.1% Y/Y) and $4.40 (FY26; +10.0%), well above consensus, supported by operational leverage and dividend cut for deleveraging. Transformational cost savings of >$200M by FY25 and $275M by FY26, driving margin expansion and multi-year EPS acceleration.
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
SAN DIEGO , May 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-organon-co-investigation-ogn.html You can also contact attorneys J.C.
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE:OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.